Evidence map›Paper›PMID 30557369›Full record

ArticlePloS one2018

Genome-wide association study (GWAS) of ovarian cancer in Japanese predicted regulatory variants in 22q13.1.

Varalee Yodsurang, Yaqi Tang, Yukie Takahashi, Chizu Tanikawa, Yoichiro Kamatani, Atsushi Takahashi, Yukihide Momozawa, Nobuo Fuse, Junichi Sugawara, Atsushi Shimizu and 13 more

Open access · goldAbstract read
In one paragraph

Article in PloS one, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
1.7field-weighted citation impact, top 14% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 11 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

23 authors at 10 institutions in 2 countries.

Varalee YodsurangLaboratory of Clinical Genome Sequencing, Department of Computational Biology and Medical Sciences, Graduate School of Frontier Sciences, The University of Tokyo, Tokyo, Japan.ORCID 0000-0002-3622-532X
Yaqi TangLaboratory of Clinical Genome Sequencing, Department of Computational Biology and Medical Sciences, Graduate School of Frontier Sciences, The University of Tokyo, Tokyo, Japan.
Yukie TakahashiLaboratory of Clinical Genome Sequencing, Department of Computational Biology and Medical Sciences, Graduate School of Frontier Sciences, The University of Tokyo, Tokyo, Japan.
Chizu TanikawaLaboratory of Genome Technology, Human Genome Center, Institute of Medical Science, The University of Tokyo, Tokyo, Japan.
Yoichiro KamataniRIKEN Center for Integrative Medical Sciences, Kanagawa, Japan.
Atsushi TakahashiRIKEN Center for Integrative Medical Sciences, Kanagawa, Japan.
Yukihide MomozawaRIKEN Center for Integrative Medical Sciences, Kanagawa, Japan.
Nobuo FuseTohoku Medical Megabank Organization, Tohoku University, Sendai, Japan.
Junichi SugawaraTohoku Medical Megabank Organization, Tohoku University, Sendai, Japan.
Atsushi ShimizuIwate Tohoku Medical Megabank Organization, Iwate Medical University, Iwate, Japan.ORCID 0000-0001-8307-2461
Akimune FukushimaIwate Tohoku Medical Megabank Organization, Iwate Medical University, Iwate, Japan.
Asahi HishidaDepartment of Preventive Medicine, Nagoya University Graduate School of Medicine, Nagoya, Japan.ORCID 0000-0002-4867-0201
Norihiro FurusyoDepartment of Environmental Medicine and Infectious Disease, Kyushu University, Fukuoka, Japan.
Mariko NaitoDepartment of Preventive Medicine, Nagoya University Graduate School of Medicine, Nagoya, Japan.
Kenji WakaiDepartment of Preventive Medicine, Nagoya University Graduate School of Medicine, Nagoya, Japan.
Taiki YamajiDivision of Epidemiology, Center for Public Health Sciences, National Cancer Center, Tokyo, Japan.
Norie SawadaDivision of Epidemiology, Center for Public Health Sciences, National Cancer Center, Tokyo, Japan.ORCID 0000-0002-9936-1476
Motoki IwasakiDivision of Epidemiology, Center for Public Health Sciences, National Cancer Center, Tokyo, Japan.
Shoichiro TsuganeCenter for Public Health Sciences, National Cancer Center, Tokyo, Japan.
Makoto HirataLaboratory of Genome Technology, Human Genome Center, Institute of Medical Science, The University of Tokyo, Tokyo, Japan.
Yoshinori MurakamiDivision of Molecular Pathology, The Institute of Medical Science, The University of Tokyo, Tokyo, Japan.
Michiaki KuboRIKEN Center for Integrative Medical Sciences, Kanagawa, Japan.
Koichi MatsudaLaboratory of Clinical Genome Sequencing, Department of Computational Biology and Medical Sciences, Graduate School of Frontier Sciences, The University of Tokyo, Tokyo, Japan.ORCID 0000-0001-7292-2686
The University of Tokyo · JPRIKEN Center for Integrative Medical Sciences · JPNational Center for Global Health and Medicine · JPIwate Medical University · JPNagoya University · JPTohoku University · JPHiroshima University · JPKyushu University · JPTeikyo University Chiba Medical Center · JPUniversité Claude Bernard Lyon 1 · FR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Genome-wide association studies (GWAS) have identified greater than 30 variants associated with ovarian cancer, but most of these variants were investigated in European populations. Here, we integrated GWAS and subsequent functional analyses to identify the genetic variants with potential regulatory effects. We conducted GWAS for ovarian cancer using 681 Japanese cases and 17,492 controls and found that rs137672 on 22q13.1 exhibited a strong association with a P-value of 1.05 × 10(-7) and an odds ratio of 0.573 with a 95% confidence interval of 0.466-0.703. In addition, three previously reported SNPs, i.e., rs10088218, rs9870207 and rs1400482, were validated in the Japanese population (P < 0.05) with the same risk allele as noted in previous studies. Functional studies including regulatory feature analysis and electrophoretic mobility shift assay (EMSA) revealed two regulatory SNPs in 22q13.1, rs2072872 and rs6509, that affect the binding affinity to some nuclear proteins in ovarian cancer cells. The plausible regulatory proteins whose motifs could be affected by the allele changes of these two SNPs were also proposed. Moreover, the protective G allele of rs6509 was associated with a decreased SYNGR1 expression level in normal ovarian tissues. Our findings elucidated the regulatory variants in 22q13.1 that are associated with ovarian cancer risk.

Indexed as

Genetic VariationGenome-Wide Association StudyAgedAllelesCase-Control StudiesChromosomes, Human, Pair 22FemaleGenotyping TechniquesHumansJapanMiddle AgedOvarian NeoplasmsPolymorphism, Single Nucleotide

Identifiers

PMID30557369
PMCPMC6296504
OpenAlexW2904864868

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.